



**CODA-CERVA**

VETERINARY AND AGROCHEMICAL RESEARCH CENTRE

GROESELBERG 99 – B 1180 BRUSSELS (UKKEL)

TEL: +32 (0)2 379 04 11

FAX : + 32 (0)2 379 06 70

HTTP: // WWW.CODA-CERVA.BE



172-PT

## **PROFICIENCY TESTING 2017**

***BOVINE SPONGIFORM ENCEPHALOPATHY (BSE)***

***Detection of BSE-specific prion antigens in bovine brain tissue***

***by Enzyme Linked Immunosorbent Assay (ELISA)***

**CODA-CERVA-UCCLE**

**DATE BEGIN PT: 09 OCTOBER 2017**

**DATE REPORT: 16 NOVEMBER 2017**

## I. Introduction

Details relevant to the proficiency test (PT) are available in the Procedure PRO/2.5/01 'Beheer van de proficiency testen op het CODA-CERVA-Ukkel/Gestion des essais d'aptitude au CODA-CERVA-Uccle', which is summarized in the 'Manual for the participant'.

## II. Aim

The aim of this PT was to evaluate the ability of the participating laboratories to identify BSE-specific prion antigens in bovine brain tissue (obex) by ELISA.

## III. Materials and methods

### III.1. Conduct of diagnostic tests

In the framework of this PT, predefined reference brain tissue samples must be tested by means of a BSE antigen ELISA. The procedures for the ELISA tests must be fully described in the SOPs of the participating laboratories.

### III.2. Reference samples

Replicates of 5 reference brain tissue samples of bovine origin, either free from detectable BSE-specific prion antigens (n=3; coded 'PT2017BSEELISANBr1', 'PT2017BSEELISANBr2' and 'PT2017BSEELISANBr3') or containing detectable BSE-specific prion antigens (n=2; coded 'PT2017BSEELISAPBr1' and 'PT2017BSEELISAPBr2'), were used. In total, 10 aliquots of these reference brain tissue samples were distributed to 2 participating laboratories. All participants received 1 aliquot of each reference brain tissue sample. The identification numbers of the reference brain tissue samples were randomized for each participant (Table 3).

For each reference brain tissue sample, a certificate containing the status of the sample (= 'golden standard') was made by the BSE reference laboratory of CODA-CERVA-Uccle based on the test results obtained during pre-verification using the TeSeE ELISA kit from Bio-Rad. All reference brain tissue samples were also tested after the PT using the same ELISA kit in order to confirm their stability and status (post-verification). Consequently, these reference brain tissue samples were considered as reliable samples to evaluate the ability of laboratories to correctly identify the absence or presence of BSE-specific prion antigens in bovine brain tissue.

### III.3. Classification of results, level of agreement and threshold for qualification

#### III.3.1. Classification of results

Results provided by the participating laboratories are categorized as *success* when the reported result matches with the assigned status or *failure* when the reported result does not match with the assigned status.

#### III.3.2. Level of agreement

The level of agreement achieved by the participating laboratories is expressed as the percentage of *success* for the 5 aliquots of reference samples used for this PT.

#### III.3.3. Threshold for qualification

Following the procedure, a participating laboratory is only qualified if the level of agreement for the 5 aliquots of reference samples is 100%.

## IV. Results

For confidentiality reasons, the participating laboratories are quoted anonymously and the concordance table is safely kept at the CODA-CERVA-Uccle.

### IV.1. Transfer and start of the analyses of the reference samples

The 5 aliquots of reference brain tissue samples were sent frozen (dry ice) to each of the 2 participating laboratories by national courier on 9<sup>th</sup> of October 2017 (10 aliquots in total). All laboratories acknowledged receipt of the samples on the same day. Analyses were performed between 10<sup>th</sup> and 12<sup>th</sup> of October 2017 (Table 1).

### IV.2. Dates at which results were returned to the CODA-CERVA-Uccle

Results were submitted to the CODA-CERVA-Uccle on 13<sup>th</sup> of October. Hereby, all laboratories respected the deadline of 20<sup>th</sup> of October 2017 for submission of the results.

**Table 1.** Overview of the dates on which (i) the reference brain tissue samples were received and analyzed by the participating laboratories, and (ii) the obtained results were submitted to the CODA-CERVA-Uccle.

Laboratory	Reference samples received	Start of analysis	Submission of the results (Excel file)
LAB1	09/10/2017	10/10/2017	13/10/2017
LAB2	09/10/2017	12/10/2017	13/10/2017

### IV.3. Compliance with the procedure

All participating laboratories have provided a duly dated and signed copy of the results.

### IV.4. Qualitative data analysis

#### IV.4.1. Level of agreement

Qualitative data analysis showed that all participating laboratories provided qualitative results that were in full agreement with the assigned status of the reference brain tissue samples (100% of agreement) (Table 2).

**Table 2.** Agreement between results obtained by the participating laboratories (LABNR) and the status of the reference brain tissue samples assigned by the BSE reference laboratory of CODA-CERVA-Uccle. All participating laboratories received 5 aliquots of reference brain tissue samples. Results are presented as absolute values and percentages (in parentheses).

	LABNR	
	1	2
failure	0 (0)	0 (0)
success	5 (100)	5 (100)

#### IV.4.2. Variability among participating laboratories

No variability in qualitative laboratory results could be observed between participating laboratories since all participants reached 100% of agreement for the detection of BSE-specific prion antigens in reference brain tissue samples.

For each participating laboratory, the obtained results and the assigned statuses for the reference brain tissue samples are shown in Table 3.

**Table 3.** The responses (RESULT) of the participating laboratories (LABNR) with the internal identification of the reference brain tissue samples (SAMPLE), the external identification of the reference brain tissue samples (LABPOSIT), and the status assigned by the BSE reference laboratory of CODA-CERVA-Uccle (STATUS). NEG: negative; POS: positive.

	LABNR	LABPOSIT	SAMPLE	STATUS	RESULT	SUCCESS
1	1	1	PT2017BSEELISANBr2	NEG	NEG	1
2	1	2	PT2017BSEELISAPBr1	POS	POS	1
3	1	3	PT2017BSEELISANBr1	NEG	NEG	1
4	1	4	PT2017BSEELISANBr3	NEG	NEG	1
5	1	5	PT2017BSEELISAPBr2	POS	POS	1
6	2	1	PT2017BSEELISANBr3	NEG	NEG	1
7	2	2	PT2017BSEELISAPBr2	POS	POS	1
8	2	3	PT2017BSEELISAPBr1	POS	POS	1
9	2	4	PT2017BSEELISANBr2	NEG	NEG	1
10	2	5	PT2017BSEELISANBr1	NEG	NEG	1

## V. Discussion

The purpose of this PT was to assess the performances of the participating laboratories when analyzing reference brain tissue samples of bovine origin for the detection of BSE-specific prion antigens by ELISA.

All participating laboratories provided qualitative results that were in full agreement with the assigned status of the reference brain tissue samples (100% of agreement) (Table 2 and Table 3). Hereby, one participant used the HerdCheck BSE-Scrapie Antigen Test Kit of IDEXX (batch GN925) and the other participant used the TeSeE ELISA kit of Biorad (batch 7F0067).

## VI. Conclusions

According to the procedure currently in force, the performance of a participating laboratory is satisfactory if 100% of the results provided by this laboratory is in agreement with the status of the reference brain tissue samples assigned by the BSE reference laboratory of CODA-CERVA-Uccle (see III.3.3.). Consequently, all participants achieved a satisfactory performance for the detection of BSE-specific prion antigens in reference brain tissue samples by ELISA.

Coordinator proficiency tests

Katia Knapen

# Appendix

## Name of the participating laboratories

Laboratorium ECCA NV (Merelbeke, Belgium)

Veterinary and Agrochemical Research Center (CODA-CERVA) (Ukkel, Belgium)